“The decision to initiate the assessment is based on preliminary laboratory findings and early clinical trials in adults ... EMA will evaluate data as it becomes available.
The assessment will continue until enough evidence has been collected to formally apply for a marketing authorization, ”the press release said.
The EU clarified that the drug will be tested for compliance with EU standards for efficacy, safety and quality.
Currently, the regulator is already conducting a gradual review procedure for Sinovac, CureVac, Novavax and Sputnik V vaccines.
In total, four vaccines are approved for use in adults in the EU: Pfizer / BioNTech, Moderna, AstraZeneca and Johnson & Johnson.
Earlier, the regulator said that the process of evaluating "Sputnik V" in the EU continues.